Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.44 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | BTK | Q06187 | 3/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16333578 | 0.90 | SIRT2 (0.45) | SIRT2HCRTR1ALDH1A1KDM4ERAB9A | |
| SCHEMBL16319903 | 0.89 | ALDH1A1 (0.44) | SIRT2HCRTR1ALDH1A1KDM4ERAB9A | |
| SCHEMBL16320530 | 0.89 | BTK (0.43) | SIRT2HCRTR1ALDH1A1KDM4ERAB9A | |
| SCHEMBL18975629 | 0.87 | BTK (0.43) | JAK2BTK | |
| SCHEMBL150341 | 0.86 | HCRTR1 (0.47) | SIRT2HCRTR1ALDH1A1KDM4ERAB9A | |
| SCHEMBL28054159 | 0.85 | JAK2 (0.47) | JAK2BTKPARP1DYRK1A | |
| SCHEMBL15994245 | 0.85 | SIRT2 (0.43) | SIRT2HCRTR1ALDH1A1KDM4ERAB9A | |
| SCHEMBL141460 | 0.82 | JAK2 (0.50) | SIRT2HCRTR1ALDH1A1KDM4ERAB9A | |
| SCHEMBL16320053 | 0.80 | SIRT2 (0.43) | SIRT2HCRTR1ALDH1A1KDM4ERAB9A | |
| SCHEMBL18976362 | 0.77 | EIF4A3 (0.41) | JAK2BTKDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10435415-B2 | Substituted tetrahydrocarbazole and carbazole carboxamide compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-10-08 | — | — | US | disclosed |
| US-10435415-B2 | Substituted tetrahydrocarbazole and carbazole carboxamide compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-10-08 | — | — | US | disclosed |
| US-20190023719-A1 | SUBSTITUTED TETRAHYDROCARBAZOLE AND CARBAZOLE CARBOXAMIDE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2019-01-24 | — | — | US | disclosed |
| US-20190023719-A1 | SUBSTITUTED TETRAHYDROCARBAZOLE AND CARBAZOLE CARBOXAMIDE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2019-01-24 | — | — | US | disclosed |
| US-10106559-B2 | Substituted tetrahydrocarbazole and carbazole carboxamide compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-10-23 | — | — | US | disclosed |
| US-20180079758-A1 | SUBSTITUTED TETRAHYDROCARBAZOLE AND CARBAZOLE CARBOXAMIDE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2018-03-22 | — | — | US | disclosed |
| US-20180079758-A1 | SUBSTITUTED TETRAHYDROCARBAZOLE AND CARBAZOLE CARBOXAMIDE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2018-03-22 | — | — | US | disclosed |
| US-9850258-B2 | Substituted tetrahydrocarbazole and carbazole carboxamide compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-12-26 | — | — | US | disclosed |
| US-9850258-B2 | Substituted tetrahydrocarbazole and carbazole carboxamide compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-12-26 | — | — | US | disclosed |
| US-20170283438-A1 | SUBSTITUTED TETRAHYDROCARBAZOLE AND CARBAZOLE CARBOXAMIDE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2017-10-05 | — | — | US | disclosed |
| US-9334290-B2 | Substituted tetrahydrocarbazole and carbazole carboxamide compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-05-10 | — | — | US | disclosed |
| US-9334290-B2 | Substituted tetrahydrocarbazole and carbazole carboxamide compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-05-10 | — | — | US | disclosed |
| EP-3013814-A1 | SUBSTITUTED TETRAHYDROCARBAZOLE AND CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2016-05-04 | — | — | EP | disclosed |
| WO-2014210085-A9 | SUBSTITUTED TETRAHYDROCARBAZOLE AND CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-12-23 | — | — | WO | disclosed |
| WO-2014210085-A9 | SUBSTITUTED TETRAHYDROCARBAZOLE AND CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-12-23 | — | — | WO | disclosed |
| US-8927718-B2 | Fused heterocyclic ring derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-01-06 | — | — | US | disclosed |
| WO-2014210085-A1 | SUBSTITUTED TETRAHYDROCARBAZOLE AND CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-12-31 | — | — | WO | disclosed |
| WO-2014210085-A1 | SUBSTITUTED TETRAHYDROCARBAZOLE AND CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-12-31 | — | — | WO | disclosed |
| US-20140378475-A1 | SUBSTITUTED TETRAHYDROCARBAZOLE AND CARBAZOLE CARBOXAMIDE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2014-12-25 | — | — | US | disclosed |
| US-20140378475-A1 | SUBSTITUTED TETRAHYDROCARBAZOLE AND CARBAZOLE CARBOXAMIDE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2014-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378475-A1 | SUBSTITUTED TETRAHYDROCARBAZOLE AND CARBAZOLE CARBOXAMIDE COMPOUNDS | BTK, CNKSR1, JAK2 | SIRT2 766/4885HCRTR1 1287/4885ALDH1A1 3286/4885 |
| US-20180079758-A1 | SUBSTITUTED TETRAHYDROCARBAZOLE AND CARBAZOLE CARBOXAMIDE COMPOUNDS | BTK, CNKSR1, JAK2 | SIRT2 766/4885HCRTR1 1287/4885ALDH1A1 3286/4885 |
| US-20190023719-A1 | SUBSTITUTED TETRAHYDROCARBAZOLE AND CARBAZOLE CARBOXAMIDE COMPOUNDS | BTK, CNKSR1, JAK2 | SIRT2 766/4885HCRTR1 1287/4885ALDH1A1 3286/4885 |
| US-20170283438-A1 | SUBSTITUTED TETRAHYDROCARBAZOLE AND CARBAZOLE CARBOXAMIDE COMPOUNDS | BTK, CNKSR1, JAK2 | SIRT2 766/4885HCRTR1 1287/4885ALDH1A1 3286/4885 |
| US-10106559-B2 | Substituted tetrahydrocarbazole and carbazole carboxamide compounds | BTK, CNKSR1, JAK2 | SIRT2 766/4885HCRTR1 1287/4885ALDH1A1 3286/4885 |
| US-10435415-B2 | Substituted tetrahydrocarbazole and carbazole carboxamide compounds | BTK, CNKSR1, JAK2 | SIRT2 766/4885HCRTR1 1287/4885ALDH1A1 3286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.